Melbourne Cancer Care
Welcome,         Profile    Billing    Logout  
 1 Trial 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
White, Michelle
Decrescendo, NCT04675827: De-escalation Adjuvant Chemo in HER2+/ER-/Node-neg Early BC Patients Who Achieved pCR After Neoadjuvant Chemo & Dual HER2 Blockade

Suspended
2
1065
Europe, RoW
Pertuzumab and tratuzumab fixed dose combination, Adjuvant pertuzumab + trastuzumab FDC SC for 14 cycles, Fixed-dose combination of Perjeta and Herceptin for subcutaneous injection for 14 cycles, Trastuzumab emtansine, Adjuvant T-DM1
Jules Bordet Institute, Breast International Group, Hoffmann-La Roche, International Drug Development Institute, Institut Curie
HER2-positive Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer, Node-negative Breast Cancer
06/27
03/29
AARC, NCT05711979: African American Resilient Caregivers

Terminated
N/A
4
US
AARC
Duke University, National Institutes of Health (NIH), National Center for Advancing Translational Sciences (NCATS)
Obesity, Childhood
03/23
03/23
NCT03763604: Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

Available
N/A
Europe, Canada, RoW
Abemaciclib, LY2835219
Eli Lilly and Company
Metastatic Breast Cancer
 
 
AARC, NCT06458790: Black Resilient Caregivers

Not yet recruiting
N/A
24
US
AARC
Duke University, Duke Pediatrics, Children's Health and Discovery Initiative
Obesity, Childhood
10/25
10/25

Download Options